Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 5 mg - glipizide tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide tablets are contraindicated in patients with: 1. known hypersensitivity to the drug. 2. type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 5 mg - glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide tablets are contraindicated in patients with:     1. known hypersensitivity to the drug.     2. type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 5 mg - glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide tablets are contraindicated in patients with:     1. known hypersensitivity to the drug.     2. type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

actavis pharma, inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 5 mg - glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide tablets are contraindicated in patients with:     1. known hypersensitivity to the drug.     2. type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 10 mg - glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide extended-release tablets are contraindicated in patients with: - known hypersensitivity to glipizide or any excipients in the tablets. known hypersensitivity to glipizide or any excipients in the tablets. - type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

state of florida doh central pharmacy - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 5 mg - glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide tablets are contraindicated in patients with: - known hypersensitivity to the drug. - type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

tya pharmaceuticals - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide 5 mg - glyburide tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets are contraindicated in patients: - with known hypersensitivity the drug or any of its excipients. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes mellitus. - concomitant administration of bosentan. warnings special warning on increased risk of cardiovascular mortality the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. this warning is based on the study conducted by the university group diabetes program (ugdp), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. the study involved 823 patients who were randomly assigned

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide 1.5 mg - glyburide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets are contraindicated in patients with:

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide 1.25 mg - glyburide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide is contraindicated in patients: - with known hypersensitivity to the drug or any of its excipients. - with type 1 diabetes mellitus or diabetic ketoacidosis, with or without coma. these conditions should be treated with insulin. - treated with bosentan.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - tolazamide (unii: 9lt1bro48q) (tolazamide - unii:9lt1bro48q) - tolazamide 250 mg - tolazamide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. tolazamide is contraindicated in patients with: - known hypersensitivity or allergy to the drug. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes, as sole therapy.